Arbutus Biopharma Corporation (ABUS) Reports Q1 2026 Results

On May 13, 2026, Arbutus Biopharma Corporation (NASDAQ:ABUS) reported Q1 2026 gross of $179.1 cardinal with estimated licence gross tied to its litigation colony with Moderna. The institution said gross jumped from $1.8 cardinal a twelvemonth earlier due to the fact that of the summation successful its stock of a noncontingent colony outgo done Genevant Sciences.

Arbutus Biopharma Corporation (NASDAQ:ABUS) reported nett income of $169.7 cardinal from a $24.5 cardinal loss. The probe and improvement expenses dropped to $4.1 cardinal from $9.0 cardinal with outgo reductions and little proceedings activity. General and administrative expenses edged higher to $5.9 cardinal owed to ineligible costs, the institution added.

Separately, the steadfast said the US Food and Drug Administration granted Fast Track designation to imdusiran. It noted that the programme could velocity up improvement and reappraisal timelines.

The corp ended the 4th with $95.2 cardinal successful currency and investments, making its fiscal presumption solid, it said.

Arbutus Biopharma Corporation (NASDAQ:ABUS) is simply a clinical-stage biopharmaceutical firm. It is progressive successful processing caller therapeutics that people circumstantial viral diseases.

While we admit the imaginable of ABUS arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.